Scott Nelson Live

In this episode, we sat down with Sina Habibi, CEO of Cognetivity.

Sina has a Ph.D. in engineering from the University of Cambridge, where he met his business partner Seyed-Mahdi Khaligh-Razavi. The two co-founded Cognetivity Neurosciences, which develops cognitive assessment tests for clinicians and patients to detect cognitive impairment, including dementia. 

In this discussion, Sina shares the importance of collaborating with regulators and end users, why he primarily focuses on the value of revenue generation versus cost savings, and the benefits of teaming up with an expert fundraiser. 

In this episode, we sat down with Olivier Delporte, CEO of Miracor Medical.

Olivier has more than 20 years of sales, marketing, and general management experience, mostly in the medical device industry. In 2016, he became the CEO of Miracor Medical, a medical device company based in Belgium. Under Olivier’s guidance, the company is advancing its flagship PiCSO treatment for severe myocardial infarction.  

In this discussion, Olivier explains why he advocates for randomized clinical trials, how remote monitoring tools can make clinical trial programs more efficient, and why startups should increase their fundraising goals.  

In this episode, we sat down with Laura Yecies, CEO of Bone Health Technologies.

Laura is a Silicon Valley veteran with more than three decades of experience at major tech companies and startups. She’s always had an interest in improving people’s health and wellness and was drawn to medtech startup Bone Health Technologies, which is developing a vibration belt intended to prevent osteoporosis.

In this discussion, Laura shares why you should look for investors who are passionate about your mission, how FDA clearance can boost consumer confidence in your technology, and why patients should be at the center of everything you do.

In this episode, we sat down with Justin Zenanko and Greg Molnar, co-founders of SynerFuse.

Justin is a Certified Public Accountant who previously led fundraising efforts at Recombinetics and Greg is the former Director of Neuromodulation Research at Medtronic. In 2018, they joined forces to build SynerFuse, a clinical-stage startup developing an innovative therapy to relieve chronic back pain.

In this discussion, the two SynerFuse co-founders share their experience launching an innovative therapy to address chronic back pain, how they are navigating challenging regulatory waters, and why they chose to invest heavily in their own venture.

In this episode, we sat down with David Neale, CEO and co-founder of Argá Medtech.David has three decades of experience bringing medical goods, services, and devices to bear across a range of sectors and in multiple countries. In 2020, he launched Argá Medtech, a multinational company focused on developing new, more efficient ways to treat atrial fibrillation. 

In this conversation, David explains how being a multinational company increased their chances of success, and why startups should incorporate economic outcomes into their clinical studies.

In this episode, we sat down with Justin Barad, Co-Founder and CEO of Osso VR.

Justin is an orthopedic surgeon with a passion for technology and a history of working in the video game industry. Using his experience and knowledge, he developed a virtual reality platform that can reform the way surgeons are trained and assessed.

In this conversation, Justin explains how he avoids being pulled in multiple directions with his technology, why it’s important to let potential customers get hands-on with your platform, and why tech can and should be fun — even in healthcare.

In this episode, we sat down with John Mastrototaro, CEO of Movano.

John has more than 30 years’ worth of experience in the medical device industry and was part of the MiniMed team that helped develop the world’s first ambulatory continuous glucose monitoring system and sensor-augmented insulin pump. John is now CEO and Director of Movano, a health technology company that makes smart, personalized devices that can provide vital health information to users. 

In this conversation, we discuss how medtech companies can build a successful consumer-facing brand while developing products that meet the needs of payers and providers.

In this episode, we sat down with Jim Biggins, Founder and CEO of Access Vascular.

Before starting the company, Jim developed innovative products for companies like Boston Scientific, Ocular Therapeutix, and Medtronic. He then spent 18 months shadowing clinicians in real-life medical settings, which led to the creation of Access Vascular's novel biomaterial for vascular access devices aimed at reducing common patient complications.

In this conversation, Jim shares the importance of hearing directly from clinicians in the field, how to plan out a clinical research strategy, and the benefit of questioning assumptions when it comes to commercialization.

In this episode, we sat down with Caroline Loew, President and CEO of Glympse Bio.

Caroline has been with Glympse Bio since 2018. Prior to that, she held executive roles at Merck and Bristol Myers Squibb, where she oversaw R&D. Caroline earned her bachelor’s and doctoral degrees at Imperial College, London. 

In this discussion, Caroline shares her “early-and-often” approach to dealing with regulatory issues and outlines four things to consider ahead of conversations with potential investors.

In this episode, we sat down with Rosina Samadani, CEO of Oculogica.

Rosina Samadani initially joined Oculogica in an advisory role, supporting her neurosurgeon sister’s plan to develop EyeBOX, a diagnostic medtech device for concussions. In 2015, Rosina transitioned into her current role as President and CEO of the company. With a doctorate in biomedical engineering from MIT, Rosina has been involved with multiple startups. She also serves as a judge for Stanford’s StartX Accelerator, and MIT’s $100K Entrepreneurship Competition. 

In this discussion,  Rosina shares the importance of relationships in the regulatory and reimbursement processes, why first-time entrepreneurs shouldn’t be intimidated by complex procedures, and lessons learned from her experiences raising capital.